Opera's shares soared nearly 18% after the browser company integrated Tether's dominant USDT stablecoin into its MiniPay wallet, highlighting investor optimism around its Web3 strategy despite unanswered questions on long-term monetization.
An AI-driven analysis suggests Cloudflare (NET) shares may face headwinds over the next two months, projecting an average price near $168. The forecast contrasts with bullish long-term analyst views, highlighting the tension between immediate technical signals and the company's strategic positioning in edge security and AI infrastructure.
The Trump administration is launching a strategic reserve for rare earths and critical minerals, echoing the 1970s response to the oil crisis, as global competition for tech supply chains intensifies.
The data analytics firm smashed Wall Street forecasts for the fourth quarter, reporting a 70% revenue surge to $1.4 billion, driven by explosive growth in its U.S. operations. Its bullish outlook for 2025 further signals resilience amid sector-wide anxieties.
As AMD prepares to release its fourth-quarter results, the chipmaker finds itself at a critical juncture, balancing Wall Street's anxiety over AI infrastructure costs against its aggressive push to challenge Nvidia's dominance with new data center and PC products.
Bernstein analyst lifts ASML's price target to $1,911, citing a buying opportunity after recent pullback. The chip equipment giant's record Q4 orders and updated guidance signal confidence in the AI-driven semiconductor upcycle.
Despite recent sharp declines triggered by Fed nomination news, JPMorgan analysts reaffirm a bullish $6,300 per ounce gold target for 2026, citing resilient demand from central banks and investors.
As Palantir Technologies prepares to report Q4 results, soaring demand for its AI platform collides with sky-high valuations, leaving investors to weigh robust growth against bubble fears.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
UPS's ambitious free cash flow target for 2026 appears to secure its hefty dividend, but a closer look reveals reliance on asset sales, deep cost cuts, and reduced capital investment—a strategy that may be mortgaging its long-term expansion.
The narrative around Chinese electric vehicles is undergoing a fundamental shift. Once known primarily for affordability, leading Chinese automakers are now challenging incumbents with rapidly improving quality, technology, and reliability, forcing a global industry recalibration.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
A historic winter storm has plunged American Airlines into its worst weather-related crisis, stranding crews and passengers while wiping up to $200 million from its revenue, exposing deep-seated recovery challenges.
A new study reveals the cost gap between Waymo's driverless vehicles and human-driven Uber and Lyft rides is shrinking, signaling a pivotal moment for the competitive robotaxi industry.
CNBC's Jim Cramer expressed reservations about aviation services provider AAR Corp., highlighting its 15% gross yield as a potential red flag for investors during a recent market analysis segment.
CNBC's Jim Cramer expressed renewed bullishness on Tesla, shifting focus from its electric vehicle business to its ambitions in robotics and autonomous 'Cybercab' technology following the company's latest earnings call.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
A second major winter storm in as many weeks has crippled logistics across the Southeast, leading to massive service suspensions, a deadly 100-car pileup, and worsening a freight backlog that saw volumes plummet over 55%.
Personal finance icon Suze Orman echoes a timeless principle from Napoleon Hill's 'Think and Grow Rich': the battle for wealth is won or lost in the mind. Experts argue that self-doubt, not market conditions, is the primary barrier most people face.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
